My Screeners
No screeners
System Screeners
My Watchlists
No watchlists
System Watchlists
Loading...
Active Biotech AB (publ) develops immunomodulatory therapeutics, focusing its primary business on internally owned small-molecule drug candidates for hematological malignancies and inflammatory eye diseases. The lead molecule, tasquinimod, is in clinical development for myelofibrosis and has also advanced in studies for multiple myeloma. A second owned program, laquinimod, is being developed as a topical ophthalmic formulation for non-infectious uveitis, with completed Phase I clinical and biodistribution studies. The company also holds a partnered immunotherapy project, naptumomab estafenatox (naptumomab), in clinical trials for advanced solid tumors under a license to NeoTX Therapeutics.
Beyond its core development pipeline, the business model emphasizes advancing programs into clinical phases internally and then engaging external partners or licensees to carry them further. The company has sharpened its commercial strategy for laquinimod by seeking an ophthalmology-specialized partner to support its continued development. Intellectual property protection is maintained for key formulations and indications, including patents for tasquinimod formulations and ocular delivery of laquinimod. Regulatory interactions include feedback from authorities such as the US FDA on study protocols, particularly for tasquinimod.
Active Biotech is based in Lund, Sweden and develops therapeutics for specialist indications with unmet medical needs, particularly rare or niche diseases. The company engages in early to mid-stage clinical development, conducting safety, biodistribution and proof-of-concept studies. It leverages academic and institutional collaborations for research and trials. Commercialization is expected through partnerships, rather than full internal commercialization.
Click to see warnings
Effective scoring profile: Standard company
Remaining score inputs are provider supplied.
Log in to see details
Log in for full accessLog in to see details
Log in for full accessLog in to see details
Log in for full accessLog in to see details
Log in for full accessLog in to see details
Log in for full accessLog in to see details
Log in for full accessLog in to see details
Log in for full accessLog in to see financial data
Log in for full accessIt is important that you understand how Findx arrives at Fair Value. Please take a minute to watch this short explainer.
It is very important that you understand this
Fair Value is an estimate, and you choose the basis it is built on. Do not invest based on our default without understanding how we calculate it.